Milnacipran
Idiopathic Peripheral Neuropathy
Columbia UniversitySmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Idiopathic Peripheral Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin University of Rochester | Phase 2 | CCC |
Duloxetine University of Rochester | Phase 2 | CCC |
Same molecule, other indications
Milnacipran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →